Participant fulfilling eligibility criteria and providing fully informed written consent

RANDOMISE
(2:1 in favour of active)

2 weekly s/c injections adalumimab, plus MTX
n = 102

2 weekly s/c injections placebo plus MTX
n = 52

Treatment Months 1 to 3
Monthly OPD review: completion of QoL and Health Economic questionnaires, AE review, ophthalmology and rheumatology review:
Treatment failure?

No

Treatment Months 4 to 18
Three Monthly OPD review: completion of QoL and Health Economic questionnaires, AE review, ophthalmology and rheumatology review:
Treatment failure?

No

Post-treatment Follow-up
Three Monthly OPD review: completion of QoL and Health Economic questionnaires, AE review, ophthalmology and rheumatology review. Any additional treatment administered at discretion of treating physician and recorded on CRF

Yes

Cease trial treatment